The IFNAR2 Knockout SK-HEP-1 Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population derived from the SK-HEP-1 human liver adenocarcinoma cell line. This product provides a loss-of-function model for the IFNAR2 gene, which encodes the beta subunit of the type I interferon receptor. The polyclonal knockout format ensures a heterogeneous population of cells with disrupted IFNAR2 alleles, suitable for studying interferon-dependent responses without clonal artifacts. The cells enable investigation of type I interferon signaling in the context of a liver adenocarcinoma background, which exhibits both epithelial and mesenchymal phenotypes.
The SK-HEP-1 cell line was originally established from the ascites of a patient with adenocarcinoma of the liver. It is characterized by an intermediate phenotype, displaying both epithelial and mesenchymal characteristics, making it a valuable model for studying epithelial-mesenchymal transition and cancer biology. SK-HEP-1 cells are widely used to investigate liver cancer mechanisms, including proliferation, migration, and immune evasion. This host cell background provides a tumor-relevant context for interrogating the role of interferon signaling in hepatic malignancies.
IFNAR2 heterodimerizes with IFNAR1 upon binding of type I interferons such as IFN-alpha and IFN-beta. This interaction activates the receptor-associated kinases JAK1 and TYK2, leading to phosphorylation of STAT1 and STAT2. Phosphorylated STAT1 and STAT2 then recruit IRF9 to form the ISGF3 transcriptional complex, which translocates to the nucleus and drives expression of interferon-stimulated genes (ISGs) including ISG15, MX1, and OAS1. These ISGs mediate antiviral, antiproliferative, and immunomodulatory responses. Consequently, disruption of IFNAR2 blocks the initiation of the JAK-STAT signaling cascade downstream of type I interferons, impairing the transcriptional activation of ISGs and the broader antiviral and immune-regulatory programs.
In SK-HEP-1 cells, interferon signaling influences tumor cell-intrinsic processes such as proliferation, apoptosis resistance, and immune microenvironment interactions. Loss of IFNAR2 in this liver adenocarcinoma background enables dissection of cell-autonomous versus paracrine interferon effects. The polyclonal knockout population allows researchers to assess how heterogeneous IFNAR2 disruption impacts collective cell behavior, cytokine production, and response to viral challenge. This model is particularly relevant for studying how liver cancer cells evade interferon-mediated tumor suppression and for exploring combinatorial strategies with immune checkpoint inhibitors.
Typical applications include functional validation of interferon-dependent pathways using western blotting for IFNAR2, STAT1 phosphorylation assays, and RT-qPCR for ISG expression. Reporter assays with ISRE-luciferase constructs can quantify transcriptional responses, while virus replication assays enable investigation of antiviral mechanisms. Flow cytometry for surface IFNAR2 expression confirms target protein loss, and RNA-seq profiling reveals transcriptomic adaptations to impaired interferon signaling. This knockout tool is suitable for drug discovery screens targeting interferon pathway components, investigation of cancer-immune crosstalk, and studies of viral pathogenesis in hepatic cells. For additional information, please contact Ascent Research.
